FIELD: medicine, pharmacy.
SUBSTANCE: invention refers to biochemistry. The antibody for BLyS is stated. The invention also relates to the DNA molecule encoding the said antibody, the expression vector and the host cell to produce the said antibody. It is also proposed to use BLyS antibodies in a pharmaceutical composition and in the method for prevention and/or treatment of diseases caused by excessive proliferation of B-cells, such as systemic lupus erythematosus. The invention allows binding to BLyS with high affinity and inhibition of binding to its receptor with high BR3 specificity.
EFFECT: invention adds a new BLyS antibody concept to biochemistry with a proposal to use the antibody for prevention and/or treatment of diseases caused by excessive proliferation of B-cells.
15 cl, 10 dwg, 4 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT ANTIBODY IL4 USED FOR TREATMENT OF DISORDERS ASSOCIATED WITH FUNCTION OF IL4 | 1994 |
|
RU2162711C2 |
| ANTIBODY IGG WITH AFFINITY BINDING WITH RESPECT TO ANTIGENIC COMPLEX CD3, RECOMBINANT NUCLEIC ACIDS ENCODING ANTIBODY LIGHT AND HEAVY CHAIN, METHOD FOR PREPARING SYSTEM, METHOD FOR PREPARING ANTIBODY, METHOD FOR TREATMENT OF PATIENT | 1999 |
|
RU2244720C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING CANCER | 2009 |
|
RU2533460C2 |
| HUMANIZED ANTIBODY 6H8HU, BINDING TO TUMOUR ANTIGEN PRAME, DNA FRAGMENTS CODING SAID ANTIBODY AND ANTIGEN-BINDING ANTIBODY FRAGMENT | 2020 |
|
RU2768737C1 |
| HUMANISED 5D3HU ANTIBODY BINDING TO THE PRAME TUMOUR ANTIGEN, DNA FRAGMENTS ENCODING SAID ANTIBODY, AND ANTIGEN-BINDING FRAGMENT OF THE ANTIBODY | 2020 |
|
RU2761876C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER | 2014 |
|
RU2678138C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| HUMANISED ANTIBODY AND ANTIGENBINDING FRAGMENT (Fab), WHICH BINDS WITH HUMAN INTERFERON-γ, DNA FRAGMENTS CODING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT, CELL, TRANSFORMED BY DNA FRAGMENT, AND METHOD OF OBTAINING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT | 2013 |
|
RU2539752C2 |
| HUMANISED NEUTRALIZING ANTIBODY TO HUMAN INTERFERON-BETA | 2019 |
|
RU2737466C1 |
| NEW COMPLETELY HUMAN VAP-1 MONOCLONAL ANTIBODIES | 2008 |
|
RU2459832C2 |
